Mitochondria in Motion

Mitochondria in Motion is a Toronto-based biotechnology company focused on developing small molecule therapeutics for neurodegenerative disorders. The company's primary approach involves targeting mitochondrial dynamics, specifically the Miro1 protein, which plays a critical role in mitochondrial transport and quality control within neurons. By restoring the proper clearance and trafficking of mitochondria, the company aims to treat conditions such as Parkinson's disease and Amyotrophic Lateral Sclerosis (ALS). Founded on research from the University of Toronto and the Tanz Centre for Research in Neurodegenerative Diseases, the company leverages deep expertise in molecular genetics. The company is currently in the pre-clinical stage, advancing its lead programs toward potential clinical applications. Its technology addresses a fundamental pathological mechanism—mitochondrial dysfunction—that is common across several major neurological indications.